Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)

Inclusion Criteria: * Must have provided written informed consent * Age 18-75 years; * BMI 17-28 kg/m2 * Completed in a PBC study with fenofibrate(NCT06591455) Exclusion Criteria: * Coexisting liver disease of other etiologies, including viral hepatitis, chronic alcoholic hepatitis, drug-induced hepatitis, autoimmune hepatitis, hepatocellular carcinoma, etc.; * Transaminases \>5 x ULN or total bilirubin \>3 x ULN; * Pregnant or breastfeeding women, or women planning to conceive during the study period; * Allergy to fenofibrate or ursodeoxycholic acid; * Use of hepatotoxic drugs (e.g., dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for more than 2 weeks within 6 months before screening, or long-term corticosteroid use; * Variceal bleeding, hepatic encephalopathy, or ascites at diagnosis or previously; * History of severe cardiac, cerebrovascular, renal, or respiratory disease or failure, or psychiatric illness (including psychiatric illness caused by alcohol or drug abuse); * Creatinine \>1.5 x ULN and creatinine clearance \<60 mL/min; * Current use of statins (e.g., pravastatin, fluvastatin, simvastatin), other fibrates (e.g., gemfibrozil, bezafibrate), or structurally related drugs (e.g., ketoprofen); * Planned organ transplantation or previous organ transplantation; * Need for liver transplantation within 1 year according to the Mayo risk score; * Any other condition considered unsuitable for enrollment by the investigator.